has been cited by the following article(s):
|
[1]
|
Prevalence and factors associated with anemia among people living with HIV taking dolutegravir-based antiretroviral therapy at debre markos compressive specialized hospital, debre markos, northwest Ethiopia, 2024: A cross-sectional study
Therapeutic Advances in Hematology,
2026
DOI:10.1177/20406207261475903
|
|
|
|
|
[2]
|
Post-COVID-19 conditions and health effects in Africa: a scoping review
BMJ Open,
2025
DOI:10.1136/bmjopen-2024-088983
|
|
|
|
|
[3]
|
Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA study in Cameroon
AIDS Research and Therapy,
2025
DOI:10.1186/s12981-025-00826-5
|
|
|
|
|
[4]
|
Progressive Development of a New Tool for Rapid Thematic Analysis of Community Perceptions and Concerns During Health Emergencies
Global Health: Science and Practice,
2025
DOI:10.9745/GHSP-D-24-00281
|
|
|
|
|
[5]
|
Unveiling the prevalence of anaemia and its predictors among adults on highly active antiretroviral therapy in the dolutegravir era: a retrospective cross-sectional study
BMJ Open,
2024
DOI:10.1136/bmjopen-2024-086480
|
|
|
|
|
[6]
|
Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa
Advances in Infectious Diseases,
2023
DOI:10.4236/aid.2023.134054
|
|
|
|